Dorayshield recently announced another milestone in its foreign trade business: the successful delivery of 5cc tungsten alloy injection shields to a Luxembourg-based medical equipment supplier. This successful order not only marks a breakthrough for the company's medium-dose medical radiation protection products in the niche, high-end market in Western Europe, but also demonstrates its competitive edge in the international nuclear medicine protection sector, opening up new avenues for deepening China-Luxembourg medical equipment trade cooperation.
The 5cc tungsten alloy injection shield is a core piece of protective equipment suitable for medium-dose radiopharmaceutical injections in nuclear medicine clinics. It is primarily used to shield medical personnel from scattered radiation generated during the injection of a 5cc syringe. Compared to traditional protective products, this shield offers three core advantages: First, it's made of high-density tungsten alloy, achieving a radiation shielding efficiency of over 99.9%, far exceeding that of ordinary lead shields. It also eliminates the risk of lead contamination and complies with EU medical environmental standards. Second, it's precisely designed for a 5cc syringe, with a smooth interior and a clear viewing window. This ensures a snug fit and prevents movement, while allowing medical staff to clearly read the medication scale and avoid dosage errors. Third, its lightweight design is 25% lighter than similar lead shields, reducing fatigue for medical staff during prolonged hand-held operation.
Despite its small size, Luxembourg has a highly developed healthcare system and stringent quality and compliance requirements for medical equipment and accessories. When selecting partners, local medical equipment suppliers require not only EU CE certification but also third-party testing reports demonstrating radiation shielding performance and biosafety. To meet demand, Dorayshield maintains strict control throughout the entire process, from raw material procurement to finished product delivery. They select medical-grade tungsten alloy with a purity of 99.95%, perform CNC precision machining to ensure dimensional tolerances within ±0.02mm, and commission TÜV Rheinland for comprehensive testing. Ultimately, Dorayshield's comprehensive compliance documentation and superior product performance have earned customer recognition.
This export represents a significant achievement in Dorayshield's focus on the niche medical protection market and its expansion into niche, high-end Western European customers. In recent years, the company has developed specialized injection shields in sizes such as 1cc, 3cc, and 5cc, tailored to different radiopharmaceutical injection scenarios. They have also established a dedicated team to research the medical certification systems of various EU countries and provide customized compliance solutions. Their products have already entered major Western European markets such as Germany and France. Their entry into Luxembourg further strengthens the company's presence in the Western European medical protection market.
Moving forward, Dorayshield will leverage this partnership to continuously focus on the niche needs of the nuclear medicine field in Luxembourg and Western Europe, increasing its R&D and optimization of multiple-specification injection shields. Furthermore, through participation in the Luxembourg Medical Equipment Fair and establishing long-term partnerships with local distributors, Dorayshield aims to expand its reach into local medical institutions with its high-quality protective products, contributing to the safety upgrade of global nuclear medicine clinical operations and driving more targeted international growth in its foreign trade business.
